AGA releases practical guideline on medical management of Crohn's disease
USA: The American Gastroenterological Association (AGA) has released new guidelines for the medical management of moderate to severe luminal and perianal fistulizing Crohn's disease. The guideline, published in the journal Gastroenterology, outlines the benefits and risk of each drug currently available to Crohn's patients. For developing the guidelines, the researchers conducted a...
USA: The American Gastroenterological Association (AGA) has released new guidelines for the medical management of moderate to severe luminal and perianal fistulizing Crohn's disease. The guideline, published in the journal Gastroenterology, outlines the benefits and risk of each drug currently available to Crohn's patients.
For developing the guidelines, the researchers conducted a detailed review of available literature. Based on the research, AGA recommends the early introduction of biologics for patients experiencing luminal and fistulizing Crohn's disease rather than waiting until other treatments fail.
Crohn's disease, a type of inflammatory bowel disease (IBD) that causes inflammation (pain and swelling) in the gastrointestinal tract, can cause daily health problems, frequent hospitalizations, and surgery when not adequately controlled. While there is no cure for Crohn's disease, there are treatments that can help patients live symptom-free life.
"With many new drugs entering the market, clinician's ability to treat patients with Crohn's disease has improved greatly over the last 20 years," said lead author Joseph D. Feuerstein, MD, from Beth Israel Deaconess, Boston, Massachusetts. "We hope this new guideline serves as a manual for clinicians in selecting the right therapies for their patients, which should lead to improved patient outcomes and less need for invasive surgery."
Key guideline recommendations:
a. Anti-tumor necrosis factor (anti-TNF) agents or ustekinumab are recommended and vedolizumab is suggested as a first-line treatment.
b. In patients who have previously not responded to anti-TNF agents, AGA recommends ustekinumab or vedolizumab.
c. The biologic natalizumab is no longer recommended due to potential adverse events and the availability of safer treatment options.
Reference:
"AGA Clinical Practice Guidelines on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn's Disease," is published in the journal Gastroenterology.
DOI: https://www.gastrojournal.org/article/S0016-5085(21)00645-4/fulltext
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd